Fever Bark
OTHER NAME(S): Alstonia Bark, Australian Febrifuge, Australian Fever Bush, Australian Quinine, Bitterbark, Corteza de Alstonia, Devil Tree, Devil's Bit, Dita Bark, Écorce Amère d'Australie, Écorce de Quinquina, Écorce de Quinquina d'Australie, Fébrifuge Australien, Pale Mara, Pali-Mara, Quinina Australiana, Quinquina d'Australie, Alstonia constricta, feverbark, Corteza de la fiebre, Écorce fébrifuge
Overview
Fever bark is the bark of an evergreen tree called Alstonia constricta. The tree is native to Australia and grows to 15 meters tall.
Fever bark contains the chemicals yohimbine and reserpine, which can lower blood pressure. These chemicals might also be unsafe.
People use fever bark for high blood pressure, malaria, rheumatoid arthritis (RA), and many other conditions, but there is no good scientific evidence to support these uses.
Don't confuse fever bark with Cinchona, which is sometimes called fever bark or fever tree. These are not the same.
Uses
We currently have no information for Fever Bark overview.
Side Effects
When taken by mouth: Fever bark is possibly unsafe. It contains the chemicals yohimbine and reserpine, which can cause serious side effects, including depression, psychotic reactions, and heart failure.
Precautions
When taken by mouth: Fever bark is possibly unsafe. It contains the chemicals yohimbine and reserpine, which can cause serious side effects, including depression, psychotic reactions, and heart failure.
Pregnancy and breast-feeding: There isn't enough reliable information to know if fever bark is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.
Anxiety: A chemical in fever bark might make anxiety worse.
Depression: A chemical in fever bark might make depression worse.
Stomach ulcers: Some of the chemicals in fever bark might make stomach ulcers worse.
Schizophrenia: Some of the chemicals in fever bark might cause a psychotic episode.
Surgery: Some chemicals in fever bark act like stimulants and might increase the risk of bleeding. Fever bark might interfere with surgery by increasing heart rate, blood pressure, and bleeding risk. Stop using fever bark at least 2 weeks before a scheduled surgery.
Interactions
Moderate Interaction
Be cautious with this combination
- Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with Fever BarkSome medications are changed and broken down by the liver. Fever bark might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
- Medications for depression (MAOIs) interacts with Fever BarkFever bark contains a chemical called yohimbine. Yohimbine might affect the body in some of the same ways as some medications for depression called MAOIs. Taking fever bark along with MAOIs might increase the effects and side effects of MAOIs. Some common MAOIs include phenelzine (Nardil), selegiline (Zelapar), and tranylcypromine (Parnate).
- Medications for high blood pressure (Antihypertensive drugs) interacts with Fever BarkFever bark might increase or decrease blood pressure. Taking fever bark along with medications that lower blood pressure might reduce the effects of these medication or cause blood pressure to go too low. Monitor your blood pressure closely.
- Medications that decrease break down of other medications by the liver (Cytochrome P450 2D6 (CYP2D6) inhibitors) interacts with Fever BarkA chemical in fever bark, yohimbine, is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down yohimbine. This could change the effects and side effects of fever bark.
- Medications that decrease break down of other medications in the liver (Cytochrome P450 3A4 (CYP3A4) inhibitors) interacts with Fever BarkA chemical in fever bark, yohimbine, is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down yohimbine. This could change the effects and side effects of fever bark.
- Medications used during surgery (Anesthesia) interacts with Fever BarkFever bark contains a chemical called reserpine. Taking reserpine along with medications used for surgery can cause heart problems. Be sure to tell your doctor what natural products you are taking before having surgery. You should stop taking fever bark at least two weeks before surgery.
- Phenothiazines interacts with Fever BarkFever bark contains a chemical called yohimbine. Some phenothiazines have effects similar to yohimbine. Taking fever bark and phenothiazines together might increase the effects and side effects of both.
- Stimulant drugs interacts with Fever BarkStimulant drugs speed up the nervous system. By speeding up the nervous system, stimulant medications can make you feel jittery and speed up your heartbeat. Fever bark might also speed up the nervous system. Taking fever bark along with stimulant drugs might cause serious problems including increased heart rate and high blood pressure.
Minor Interaction
Be watchful with this combination
- Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with Fever BarkFever bark might slow blood clotting. Taking fever bark along with medications that also slow clotting might increase the chances of bruising and bleeding.
Dosing
There isn't enough reliable information to know what an appropriate dose of fever bark might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.
References
- Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
- Foster S, Tyler VE. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.
- The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
- Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
- McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
- McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
- Ellenhorn MJ, et al. Ellenhorn's Medical Toxicology: Diagnoses and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins, 1997.
- Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
- Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
- Sklar S, et al. Drug therapy screening system. Indianapolis, IN: First Data Bank 99.1-99. 2 eds.
- Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.
- Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998;159:122-4.
- Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22.
- Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9.
- Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother 2010;44:1022-9.
- VandenBrink, B. M., Foti, R. S., Rock, D. A., Wienkers, L. C., and Wahlstrom, J. L. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2012;40(1):47-53.
- Abebe, W. An overview of herbal supplement utilization with particular emphasis on possible interactions with dental drugs and oral manifestations. J Dent.Hyg. 2003;77(1):37-46.
- Mustonen, P., Savola, J., and Lassila, R. Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. Thromb.Res 8-1-2000;99(3):231-237.
- Cameron, O. G., Zubieta, J. K., Grunhaus, L., and Minoshima, S. Effects of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans. Psychosom.Med 2000;62(4):549-559.
- Bowes, M. P., Peters, R. H., Kernan, W. J., Jr., and Hopper, D. L. Effects of yohimbine and idazoxan on motor behaviors in male rats. Pharmacol.Biochem.Behav. 1992;41(4):707-713.
- Bagheri, H., Schmitt, L., Berlan, M., and Montastruc, J. L. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol 1992;34(6):555-558.
- Bagheri, H., Bompart, G., Girolami, J. P., Montastruc, J. L., and Montastruc, P. Is yohimbine-induced increase in salivary secretion a kinin-dependent mechanism? Fundam.Clin Pharmacol 1992;6(1):17-20.
- Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur.Arch.Psychiatry Clin.Neurosci. 1992;241(6):337-344.
- Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. Eur Arch Psychiatry Clin Neurosci. 1992;241(6):345-351.
- Adeniyi, A. A., Brindley, G. S., Pryor, J. P., and Ralph, D. J. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl 2007;9(3):403-407.
- Giampreti, A., Lonati, D., Locatelli, C., Rocchi, L., and Campailla, M. T. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol.(Phila) 2009;47(8):827-829.
- Myers, A. and Barrueto, F., Jr. Refractory priapism associated with ingestion of yohimbe extract. J Med Toxicol. 2009;5(4):223-225.
- Berlin, I., Crespo-Laumonnier, B., Cournot, A., Landault, C., Aubin, F., Legrand, J. C., and Puech, A. J. The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol.Ther. 1991;49(4):362-369.
- Cimolai, N. and Cimolai, T. Yohimbine use for physical enhancement and its potential toxicity. J Diet.Suppl 2011;8(4):346-354.
- Bagheri, H., Berlan, M., Montastruc, J. L., and Montastruc, P. Yohimbine and lacrimal secretion. Br J Clin Pharmacol. 1990;30(1):151-152.
- Landis, E. and Shore, E. Yohimbine-induced bronchospasm. Chest 1989;96(6):1424.
- Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141(6):1360-1363.
- Chatelut, E., Rispail, Y., Berlan, M., and Montastruc, J. L. Yohimbine increases human salivary secretion. Br.J Clin Pharmacol. 1989;28(3):366-368.
- Montastruc, P., Berlan, M., and Montastruc, J. L. Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol 1989;98(1):101-104.
- Charney, D. S., Price, L. H., and Heninger, G. R. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch.Gen.Psychiatry 1986;43(12):1155-1161.
- Braddock, L., Cowen, P. J., Elliott, J. M., Fraser, S., and Stump, K. Binding of yohimbine and imipramine to platelets in depressive illness. Psychol.Med 1986;16(4):765-773.
- Charney, D. S., Heninger, G. R., and Sternberg, D. E. Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 6-7-1982;30(23):2033-2041.
- Boon, N. A., Elliott, J. M., Grahame-Smith, D. G., John-Green, T., and Stump, K. A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]- dihydroergocryptine. J Auton.Pharmacol 1983;3(2):89-95.
- Brodde, O. E., Anlauf, M., Arroyo, J., Wagner, R., Weber, F., and Buck, K. D. Hypersensitivity of adrenergic receptors and blood-pressure response to oral yohimbine in orthostatic hypotension. N.Engl.J Med 4-28-1983;308(17):1033-1034.
- Charney, D. S., Heninger, G. R., and Redmond, D. E., Jr. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 7-4-1983;33(1):19-29.
- Bourin, M., Malinge, M., and Guitton, B. Provocative agents in panic disorder. Therapie 1995;50(4):301-306.
- Knoll, L. D., Benson, R. C., Jr., Bilhartz, D. L., Minich, P. J., and Furlow, W. L. A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol. 1996;155(1):144-146.
- Bagheri, H., Chale, J. J., Guyen, L. N., Tran, M. A., Berlan, M., and Montastruc, J. L. Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha 2-adrenoceptor antagonist. Fundam.Clin Pharmacol 1995;9(3):248-254.
- Morgan, C. A., III, Southwick, S. M., Grillon, C., Davis, M., Krystal, J. H., and Charney, D. S. Yohimbine-facilitated acoustic startle reflex in humans. Psychopharmacology (Berl) 1993;110(3):342-346.
- Biaggioni, I., Robertson, R. M., and Robertson, D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol. 1994;34(5):418-423.
- Mann, K., Klingler, T., Noe, S., Roschke, J., Muller, S., and Benkert, O. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch.Sex Behav. 1996;25(1):1-16.
- Rowland, D. L., Kallan, K., and Slob, A. K. Yohimbine, erectile capacity, and sexual response in men. Arch Sex Behav 1997;26(1):49-62.
- Bremner, J. D., Innis, R. B., Ng, C. K., Staib, L. H., Salomon, R. M., Bronen, R. A., Duncan, J., Southwick, S. M., Krystal, J. H., Rich, D., Zubal, G., Dey, H., Soufer, R., and Charney, D. S. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch.Gen.Psychiatry 1997;54(3):246-254.
- Gurguis, G. N., Vitton, B. J., and Uhde, T. W. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res. 6-16-1997;71(1):27-39.
- Riley AJ, Goodman R, Kellett JM, and et al. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther 1989;4(1):17-26.
- Lobay D. Rauwolfia in the Treatment of Hypertension. Integr Med (Encinitas). 2015 Jun;14(3):40-6.
- Sheldon MB, Kotte JH. Effect of Rauwolfia serpentina and reserpine on the blood pressure in essential hypertension; a long-term double-blind study. Circulation. 1957 Aug;16(2):200-6.
- Le Corre P, Parmer RJ, Kailasam MT, et al. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004;76(2):139-53.
- Mueller-Schoell A, Michelet R, Weinelt F, Kloft C, Mikus G. CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. Arch Toxicol. 2021.
- Bharucha AE, Skaar T, Andrews CN, et al Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008;20(8):891-9.